Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
MAXAQUIN (lomefloxacin hydrochloride) is an oral fluoroquinolone antibiotic approved by the FDA in 1992 for bacterial infections. It is a small-molecule synthetic antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication in susceptible organisms. The drug is indicated for respiratory tract infections, urinary tract infections, and other bacterial infections treatable by fluoroquinolones.
Product is in late-stage lifecycle with significant generic competition (30% competitive pressure), suggesting a consolidating team focused on managed decline and cost optimization.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on MAXAQUIN offers limited growth opportunities given its LOE-approaching lifecycle and zero linked job openings. Career progression is constrained to operational optimization, generic strategy, or preparation for product discontinuation. This is a defensive role suited to professionals focused on cost management and market exit strategies rather than innovation.
Worked on MAXAQUIN at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.